Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of NNC0113-6861, -6860, and -6891 Microdoses in Healthy Men
NCT04676906Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2020
- Primary completion
- Apr 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of semaglutide, NNC0113-6860 and NNC0113-6891 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Apparent elimination half-life. Started Nov 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04676906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676906.